Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a wearable sensor replace fingerstick tests in the ICU?

NCT ID NCT07687368

Disease control Sponsor: Institut d'Investigacions Biomèdiques August Pi i Sunyer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial compares continuous glucose monitoring (CGM) with standard fingerstick testing in 400 critically ill ICU patients with high blood sugar. CGM uses a small sensor under the skin to measure glucose every 5 minutes and alerts staff when levels are too high or low. The goal is to see if CGM helps keep glucose in a safe range, reduces dangerous highs and lows, and cuts down on the number of blood tests needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous Glucose Monitoring (CGM) device
What this could lead to
If it works, CGM could become routine in ICUs, improving patient safety and reducing the need for frequent fingerstick blood tests.
What could go wrong
This is a single-center trial, and results may not apply to all ICUs. CGM may not significantly improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

400 people

The number who actually took part.

Started

Jun 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or over * Stay in ICU and/or intermediate care * Blood glucose levels \>180 mg/dL (10 mmol/L). Exclusion Criteria: * Pregnancy * Contraindications for the use of CGM (such as skin issues or allergies to adhesives) * End-of-life process

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Critical care nursing Critical care, intensive care Critical illness Glucose control Hyperglycaemia

Contacts and locations

Locations

  • Carrer de Villarroel, 170

    Barcelona, Catalonia, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.